Threshold Pharmaceuticals Inc

Type: Company
Name: Threshold Pharmaceuticals Inc
Nationality: United States
Web Address: http://www.thresholdpharm.com/
First reported Jul 15 2014 - Updated Jul 15 2014 - 1 reports

Threshold to Initiate Phase 1/2 Trial

Threshold Pharmaceuticals, Inc. reported that dosing has started in the final stage of an ongoing Phase 1/2 trial of its investigational hypoxia-activated prodrug, TH-302, in combination with the proteasome inhibitor bortezomib (Velcade) and low-dose ... [Publicerad Individual.com - Jul 15 2014]
First reported Jul 14 2014 - Updated Jul 14 2014 - 1 reports

3 Health Care Stocks Primed For Big Moves

Throughout the spring, analysts at Lazard Capital and Leerink Swan kept pounding the table for little-known Insmed (Nasdaq: INSM).The analysts kept telling clients that Insmed's Arikace, which is an inhalable antiobiotic used in serious lung infections, ... [Publicerad Yahoo! Finance - Jul 14 2014]
First reported Jul 09 2014 - Updated Jul 09 2014 - 2 reports

Threshold Begins Dosing With TH-302 In Relapsed Multiple Myeloma Trial

Threshold Pharmaceuticals, Inc. (THLD: Quote) Wednesday said it has begun dosing in the final stage of an ongoing Phase 1/2 trial of its investigational drug, TH-302, in combination with the proteasome inhibitor bortezomib and low-dose dexamethasone in ... [Publicerad RTTNews.com - Jul 09 2014]
First reported Jul 08 2014 - Updated Jul 08 2014 - 1 reports

Threshold Pharmaceuticals Coverage Initiated by Analysts at Brean Capital (THLD)

Equities researchers at Brean Capital assumed coverage on shares of Threshold Pharmaceuticals (NASDAQ:THLD)Separately, analysts at Zacks upgraded shares of Threshold Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Tuesday, ... [Publicerad American Banking News - Stock Ratings - Jul 08 2014]
First reported Jul 08 2014 - Updated Jul 08 2014 - 1 reports

Threshold Initiates Phase 2 Clinical Trial In Advanced Non-Squamous Non-Small Cell Lung Cancer

By Tony Schwartz, PhD :Company OverviewRelated Biotechnology, Pharmaceutical and Healthcare NewsThreshold Pharmaceuticals ( THLD ) is a development stage biopharmaceutical company currently evaluating its lead compound, TH-302, in several clinical trials ... [Publicerad BioPortfolio - Jul 08 2014]
First reported Jul 07 2014 - Updated Jul 07 2014 - 1 reports

Threshold Pharmaceuticals Begins 440-Patient, Randomized, Double-Blind, Placebo-Controlled Trial of TH-302

Threshold Pharmaceuticals reported initiation of a 440-patient, randomized, double-blind, placebo-controlled trial of its investigational hypoxia-activated prodrug, TH-302, in combination with pemetrexed in advanced non-squamous non-small cell lung cancer ... [Publicerad Individual.com - Jul 07 2014]
First reported Jul 03 2014 - Updated Jul 03 2014 - 1 reports

Meet 'et al': The mystery man behind some of the world's most powerful drugs

The patents behind humanized monoclonal antibodies — the biotechnology behind such life-changing medicines as Genentech Inc.'s Avastin and Herceptin and Biogen Idec Inc.'s Tysabri — generally are known as the "Queen patents" for inventor Cary Queen.Look ... [Publicerad Business First of Buffalo - Jul 03 2014]
First reported Jul 01 2014 - Updated Jul 01 2014 - 1 reports

Threshold Pharmaceuticals Initiates 440-Patient, Randomized, Double-Blind, Placebo-Controlled Trial of TH-302 in Combination With Pemetrexed in Advanced Non-Squamous Non-Small Cell Lung Cancer

SOUTH SAN FRANCISCO, CA--(Marketwired - Jul 1, 2014) - Threshold Pharmaceuticals, Inc. (NASDAQ: THLD) today announced initiation of a 440-patient, randomized, double-blind, placebo-controlled trial of its investigational hypoxia-activated prodrug, TH-302, ... [Publicerad Marketwire - Breaking News Releases - Jul 01 2014]
First reported Jun 23 2014 - Updated Jun 23 2014 - 1 reports

Threshold Pharmaceuticals major shareholder David L. Anderson Sells 13,988 Shares (THLD)

Threshold Pharmaceuticals (NASDAQ:THLD) major shareholder David L. Anderson sold 13,988 shares of Threshold Pharmaceuticals stock on the open market in a transaction dated Friday, June 20th. The stock was sold at an average price of $4.01, for a total ... [Publicerad American Banking News - Jun 23 2014]
First reported May 30 2014 - Updated May 30 2014 - 2 reports

Threshold Announces Data From Ongoing Phase 1/2 Trial of TH-302 Plus Bevacizumab (Avastin(R)) in Patients With Recurrent Glioblastoma

CHICAGO, IL--(Marketwired - May 30, 2014) - Threshold Pharmaceuticals, Inc. (NASDAQ: THLD)  ... [Publicerad Marketwire - Breaking News Releases - May 30 2014]
First reported May 30 2014 - Updated May 30 2014 - 1 reports

Threshold Pharmaceuticals Announces Presentation and Webcast at the Jefferies Global Healthcare Conference

SOUTH SAN FRANCISCO, CA--(Marketwired - May 30, 2014) - Threshold Pharmaceuticals, Inc. (NASDAQ: THLD) today announced that Barry Selick, Ph.D., Threshold's Chief Executive Officer, will present a company overview at the Jefferies Global Healthcare ... [Publicerad Marketwire - Breaking News Releases - May 30 2014]
First reported May 13 2014 - Updated May 13 2014 - 1 reports

Threshold Pharmaceuticals Announces Presentation and Webcast at the UBS Global Healthcare Conference

SOUTH SAN FRANCISCO, CA--(Marketwired - May 13, 2014) - Threshold Pharmaceuticals, Inc. (NASDAQ: THLD) today announced that Barry Selick, Ph.D., Threshold's Chief Executive Officer, will present a company overview at the UBS Global Healthcare Conference ... [Publicerad Marketwire - Breaking News Releases - May 13 2014]

Quotes

"The presence of hypoxia in the diseased bone marrow may present a new therapeutic target for treating multiple myeloma and underscores my enthusiasm for further evaluation of TH-302 in this disease" said Jacob Laubach, Clinical Director of the Jerome Lipper Multiple Myeloma Center at Dana-Farber/Brigham and Women's Cancer Center and a lead investigator...
...In the interim, the company also aims to provide more extensive data regarding the tests' accuracy. "In the past, clinical studies have served as positive catalysts for GHDX shares" note Merrill's analysts
"The practice of the present technology includes the use of conventional techniques of molecular biology (including recombinant techniques), microbiology, cell biology, biochemistry and immunology, which are within the skill of the art."

More Content

All (28) | News (16) | Reports (0) | Blogs (12) | Audio/Video (0) | Fact Sheets (0) | Press Releases (0)
sort by: Date | Relevance
Data points: Economic calendar [Publicerad Frederick News-Post - Jul 28 2014]
Threshold to Initiate Phase 1/2 Trial [Publicerad Individual.com - Jul 15 2014]
3 Health Care Stocks Primed For Big Moves [Publicerad Yahoo! Finance - Jul 14 2014]
Pancreatic cancer market for the six major mark... [Publicerad Live-PR.com - Jul 14 2014]
Threshold Begins Dosing With TH-302 In Relapsed... [Publicerad RTTNews.com - Jul 09 2014]
"Methods for Treating Cancer" in Patent Applica... [Publicerad Pharmacy Choice - Jul 09 2014]
Threshold Announces Initiation of Dosing With T... [Publicerad Marketwire - Breaking News Releases - Jul 09 2014]
Top Analysts Action: MMM, CGI, ZINC, BRKR, ZBRA [Publicerad BayStreet.ca - Jul 08 2014]
Threshold Pharmaceuticals Coverage Initiated by... [Publicerad American Banking News - Stock Ratings - Jul 08 2014]
Investment Analysts’ New Coverage for July, 8th... [Publicerad American Banking News - Jul 08 2014]
Threshold Initiates Phase 2 Clinical Trial In A... [Publicerad BioPortfolio - Jul 08 2014]
Threshold Pharmaceuticals Begins 440-Patient, R... [Publicerad Individual.com - Jul 07 2014]
Meet 'et al': The mystery man behind some of th... [Publicerad Business First of Buffalo - Jul 03 2014]
Threshold Pharmaceuticals Initiates 440-Patient... [Publicerad Marketwire - Breaking News Releases - Jul 01 2014]
Pancreatic Ductal Adenocarcinoma Pipeline Revi... [Publicerad BioPortfolio - Jun 24 2014]
Threshold Pharmaceuticals major shareholder Dav... [Publicerad American Banking News - Jun 23 2014]
Threshold Announces Data From Ongoing Phase 1/2... [Publicerad Marketwire - Breaking News Releases - May 30 2014]
Threshold Announces Data From Ongoing Phase 1/2... [Publicerad Marketwire - Breaking News Releases - May 30 2014]
Threshold Pharmaceuticals Announces Presentatio... [Publicerad Marketwire - Breaking News Releases - May 30 2014]
Threshold Pharmaceuticals Announces Presentatio... [Publicerad Marketwire - Breaking News Releases - May 13 2014]
Threshold CEO Named as Finalist for European In... [Publicerad Marketwire - Breaking News Releases - May 06 2014]
Threshold Pharmaceuticals Reports First Quarter... [Publicerad Marketwire - Breaking News Releases - May 01 2014]
Neuroendocrine Cancer Global Clinical Trials Re... [Publicerad BioPortfolio - Apr 07 2014]
Threshold Pharmaceuticals Announces Results of ... [Publicerad Marketwire - Breaking News Releases - Apr 03 2014]
Threshold Pharmaceuticals' Partner Merck KGaA, ... [Publicerad Marketwire - Breaking News Releases - Mar 27 2014]
Threshold Pharmaceuticals Reports Fourth Quarte... [Publicerad Marketwire - Breaking News Releases - Mar 06 2014]
Threshold Pharmaceuticals Announces Presentatio... [Publicerad Marketwire - Breaking News Releases - Feb 20 2014]
Pancreatic Cancer Disease and Pipeline Analysis [Publicerad BioPortfolio - Jan 29 2014]
1
In Focus
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
Content Volume
Document Volume
Network
Network

Blogs

sort by: Date | Relevance
Threshold Announces Initiation of Dosing With T... [Publicerad Marketwire - Breaking News Releases - Jul 09 2014]
SOUTH SAN FRANCISCO, CA--(Marketwired - Jul 9, 2014) - Threshold Pharmaceuticals, Inc. (NASDAQ: THLD) today announced that dosing has started in the final stage of an ongoing Phase 1/2 trial of its investigational hypoxia-activated prodrug, TH-302, ...
Threshold Pharmaceuticals Initiates 440-Patient... [Publicerad Marketwire - Breaking News Releases - Jul 01 2014]
SOUTH SAN FRANCISCO, CA--(Marketwired - Jul 1, 2014) - Threshold Pharmaceuticals, Inc. (NASDAQ: THLD) today announced initiation of a 440-patient, randomized, double-blind, placebo-controlled trial of its investigational hypoxia-activated prodrug, TH-302, ...
Threshold Announces Data From Ongoing Phase 1/2... [Publicerad Marketwire - Breaking News Releases - May 30 2014]
CHICAGO, IL--(Marketwired - May 30, 2014) - Threshold Pharmaceuticals, Inc. (NASDAQ: THLD)  ...
Threshold Announces Data From Ongoing Phase 1/2... [Publicerad Marketwire - Breaking News Releases - May 30 2014]
CHICAGO, IL--(Marketwired - May 30, 2014) - Threshold Pharmaceuticals, Inc. (NASDAQ: THLD)  ...
Threshold Pharmaceuticals Announces Presentatio... [Publicerad Marketwire - Breaking News Releases - May 30 2014]
SOUTH SAN FRANCISCO, CA--(Marketwired - May 30, 2014) - Threshold Pharmaceuticals, Inc. (NASDAQ: THLD) today announced that Barry Selick, Ph.D., Threshold's Chief Executive Officer, will present a company overview at the Jefferies Global Healthcare ...
1 2 3
Contact Us
Sales
Support


Freebase CC-BY Some image thumbnails are sourced from Freebase, licensed under CC-BY

Copyright (C) 2014 Silobreaker Ltd. All rights reserved.
The selection and placement of stories and images on any Silobreaker page are determined automatically by a computer program.
The time or date displayed reflects when an article was added to or updated in Silobreaker.